Search Results - "Sennott, Erin M"

Aldolase-B knockout in mice phenocopies hereditary fructose intolerance in humans by Oppelt, Sarah A., Sennott, Erin M., Tolan, Dean R.

“…The rise in fructose consumption, and its correlation with symptoms of metabolic syndrome (MBS), has highlighted the need for a better understanding of…”
Get full text

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations by Ahronian, Leanne G, Sennott, Erin M, Van Allen, Eliezer M, Wagle, Nikhil, Kwak, Eunice L, Faris, Jason E, Godfrey, Jason T, Nishimura, Koki, Lynch, Kerry D, Mermel, Craig H, Lockerman, Elizabeth L, Kalsy, Anuj, Gurski, Jr, Joseph M, Bahl, Samira, Anderka, Kristin, Green, Lisa M, Lennon, Niall J, Huynh, Tiffany G, Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A John, Engelman, Jeffrey A, Garraway, Levi A, Corcoran, Ryan B

“…BRAF mutations occur in approximately 10% of colorectal cancers. Although RAF inhibitor monotherapy is highly effective in BRAF-mutant melanoma, response rates…”
Get more information

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer by Oddo, Daniele, Sennott, Erin M, Barault, Ludovic, Valtorta, Emanuele, Arena, Sabrina, Cassingena, Andrea, Filiciotto, Genny, Marzolla, Giulia, Elez, Elena, van Geel, Robin M J M, Bartolini, Alice, Crisafulli, Giovanni, Boscaro, Valentina, Godfrey, Jason T, Buscarino, Michela, Cancelliere, Carlotta, Linnebacher, Michael, Corti, Giorgio, Truini, Mauro, Siravegna, Giulia, Grasselli, Julieta, Gallicchio, Margherita, Bernards, René, Schellens, Jan H M, Tabernero, Josep, Engelman, Jeffrey A, Sartore-Bianchi, Andrea, Bardelli, Alberto, Siena, Salvatore, Corcoran, Ryan B, Di Nicolantonio, Federica

“…Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF-mutant colorectal cancer, emergence of acquired…”
Get full text

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination by Ham, Jungoh, Costa, Carlotta, Sano, Renata, Lochmann, Timothy L., Sennott, Erin M., Patel, Neha U., Dastur, Anahita, Gomez-Caraballo, Maria, Krytska, Kateryna, Hata, Aaron N., Floros, Konstantinos V., Hughes, Mark T., Jakubik, Charles T., Heisey, Daniel A.R., Ferrell, Justin T., Bristol, Molly L., March, Ryan J., Yates, Craig, Hicks, Mark A., Nakajima, Wataru, Gowda, Madhu, Windle, Brad E., Dozmorov, Mikhail G., Garnett, Mathew J., McDermott, Ultan, Harada, Hisashi, Taylor, Shirley M., Morgan, Iain M., Benes, Cyril H., Engelman, Jeffrey A., Mossé, Yael P., Faber, Anthony C.

“…Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor…”
Get full text

Abstract LB-055: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations by Ahronian, Leanne G., Sennott, Erin M., Van Allen, Eliezer M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Godfrey, Jason T., Nishimura, Koki, Lynch, Kerry D., Mermel, Craig H., Lockerman, Elizabeth L., Kalsy, Anuj, Gurski, Joseph M., Bahl, Samira, Anderka, Kristin, Green, Lisa M., Lennon, Niall J., Huynh, Tiffany G., Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A. John, Engelman, Jeffrey A., Garraway, Levi A., Corcoran, Ryan B.

“…Abstract BRAF V600E mutations occur in ∼10% of colorectal cancer (CRC), and are associated with poor prognosis. RAF inhibition alone has not been an effective…”
Get full text